Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.30 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2286812 | 1.00 | DPP4 (0.36) | DPP4SMN1; SMN2METAP1EPHX2ALDH1A1 | |
| SCHEMBL1550843 | 1.00 | DPP4 (0.36) | DPP4SMN1; SMN2METAP1EPHX2ALDH1A1 | |
| SCHEMBL13493236 | 0.89 | SMN1; SMN2 (0.35) | SMN1; SMN2METAP1ALDH1A1LMNAHTT | |
| SCHEMBL10034671 | 0.87 | SMN1; SMN2 (0.46) | DPP4SMN1; SMN2EPHX2ALDH1A1LMNA | |
| SCHEMBL1358814 | 0.74 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL1358812 | 0.74 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL2286807 | 0.72 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL1550841 | 0.72 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL23165799 | 0.71 | EPHX2 (0.43) | DPP4METAP1EPHX2 | |
| SCHEMBL23165798 | 0.71 | EPHX2 (0.43) | DPP4METAP1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263768-B2 | Process for the stereoselective preparation of bicyclic heterocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20120116080-A1 | PROCESS FOR THE STEREOSELECTIVE PREPARATION OF BICYCLIC HETEROCYCLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-7998949-B2 | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20100022505-A1 | BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
| WO-2008095847-A1 | BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022505-A1 | BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION THEREOF | RET, CYP11B2, CHUK | DPP4 4208/4885SMN1; SMN2 4691/4885METAP1 4244/4885 |
| US-20120116080-A1 | PROCESS FOR THE STEREOSELECTIVE PREPARATION OF BICYCLIC HETEROCYCLES | BPHL, CYP11B1, CYP11B2 | DPP4 3542/4885SMN1; SMN2 4520/4885METAP1 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.